|
|
News Breaks | | | | September 12, 2012 | | 07:08 EDT |  | OPXA | Opexa Therapeutics begin Phase IIb clinical trial of Tcelna for sclerosis
Opexa Therapeutics initiated a Phase IIb clinical trial of Tcelna, a novel T-cell therapy for multiple sclerosis, in patients with Secondary Progressive Multiple Sclerosis. Several patients have already been enrolled in the study and enrollment is expected to increase rapidly. Tcelna has received Fast Track Designation from the FDA for the treatment of SPMS. The therapy has demonstrated superior safety and encouraging indications of efficacy in previous clinical studies in MS that included the treatment of SPMS patients. There is currently only one FDA-approved treatment for SPMS but safety warnings have severely restricted its use. | |
|
News For OPXA From The Last 14 Days Check below for free stories on OPXA the last two weeks. |
|
|
| There are no results for OPXA |
|
|
|
|
|
|
